NK:IO / Imperial College London


NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours.
Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms

Get Involved with the Advanced Therapies Congress


To sponsor or exhibit

Ashlea Foster
+44 208 164 3032



To speak

Ila Dickinson
+44 207 092 1150